ArticleThe Journal of clinical endocrinology and metabolism2022
Recurrence of Papillary Thyroid Cancer: A Systematic Appraisal of Risk Factors.
Article in The Journal of clinical endocrinology and metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Meta-analysis of the effect and clinical significance of Delphian lymph node metastasis in papillary thyroid cancer.Frontiers in endocrinology · 2023Pooled it
- A seven-gene diagnostic and prognostic signature for papillary thyroid carcinoma.Discover oncology · 2026Article
- Improving predicted risk of recurrence using molecular profiling in papillary thyroid cancer.Scientific reports · 2026Article
- New Insights into the Development of Papillary Thyroid Cancer: The Roles of miR-1179 and ELF3.Cells · 2026Article
- Case Report: Diagnosis and treatment strategy for a case of multiple chest wall implantations and neck lymph node metastasis following total areola endoscopic surgery for papillary thyroid carcinoma.Frontiers in oncology · 2026Article
- Internal validation of a residual thyroid recurrence model after PTC.Frontiers in oncology · 2026Article
- Multidimensional transcriptomic and immune profiling of papillary thyroid cancer: bridging molecular networks, disease stage, survival outcomes, and drug discovery.Discover oncology · 2025Article
- Predicting the Metastatic Potential of Papillary Thyroid Microcarcinoma Based on the Molecular Profile of Preoperative Cytology Specimens.International journal of molecular sciences · 2025Article
- Predictive risk-scoring model for lateral lymph node metastasis in papillary thyroid carcinoma.Scientific reports · 2025Article
- Investigation of Scutellaria Barbata's immunological mechanism against thyroid cancer using network pharmacology and experimental validation.Scientific reports · 2025Article
- Evaluating the Relationship between Cathepsins and Papillary Thyroid Carcinoma: A Mendelian Randomization Study.Endocrine, metabolic & immune disorders drug targets · 2025Article
- Endoscopic surgery for papillary thyroid microcarcinoma: cases review and investigation of technique dissemination in China.Frontiers in endocrinology · 2025Article
- Invited commentary: Lymph node yield independently predicts local recurrence in papillary thyroid cancer.World journal of surgery · 2025Article
- Identification of LINC02454-related key pathways and genes in papillary thyroid cancer by weighted gene coexpression network analysis (WGCNA).Thyroid research · 2024Article
- Prediction of the Aggressive Clinical Course of Papillary Thyroid Carcinoma Based on Fine Needle Aspiration Biopsy Molecular Testing.International journal of molecular sciences · 2024Article
- F10 Gene Expression and Ethnic Disparities Present in Papillary Thyroid Carcinoma.Journal of personalized medicine · 2024Article
- Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks.Nature communications · 2024Article
- Combined Vorinostat and Chloroquine Inhibit Sodium-Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Novel molecular typing reveals the risk of recurrence in patients with early-stage papillary thyroid cancer.Thyroid research · 2024Article
- The prognostic power of gene mutations in thyroid cancer.Endocrine connections · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
contextThyroid cancer recurrence is associated with increased mortality and adverse outcomes. Recurrence risk is currently predicted using clinical tools, often restaging patients after treatment. Detailed understanding of recurrence risk at disease onset could lead to personalized and improved patient care.
objectiveWe aimed to perform a comprehensive bioinformatic and experimental analysis of 3 levels of genetic change (mRNA, microRNA, and somatic mutation) apparent in recurrent tumors and construct a new combinatorial prognostic risk model.
methodsWe analyzed The Cancer Genome Atlas data (TCGA) to identify differentially expressed genes (mRNA/microRNA) in 46 recurrent vs 455 nonrecurrent thyroid tumors. Two exonic mutational pipelines were used to identify somatic mutations. Functional gene analysis was performed in cell-based assays in multiple thyroid cell lines. The prognostic value of genes was evaluated with TCGA datasets.
resultsWe identified 128 new potential biomarkers associated with recurrence, including 40 mRNAs, 39 miRNAs, and 59 genetic variants. Among differentially expressed genes, modulation of FN1, ITGα3, and MET had a significant impact on thyroid cancer cell migration. Similarly, ablation of miR-486 and miR-1179 significantly increased migration of TPC-1 and SW1736 cells. We further utilized genes with a validated functional role and identified a 5-gene risk score classifier as an independent predictor of thyroid cancer recurrence.
conclusionOur newly proposed risk model based on combinatorial mRNA and microRNA expression has potential clinical utility as a prognostic indicator of recurrence. These findings should facilitate earlier prediction of recurrence with implications for improving patient outcome by tailoring treatment to disease risk and increasing posttreatment surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.